IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.

MLA

Chen, Xiangli, et al. “IDO, TDO, and AHR Overexpression Is Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era.” Medicine, vol. 99, no. 21, May 2020, p. e19883. EBSCOhost, https://doi.org/10.1097/MD.0000000000019883.

APA

Chen, X., Zang, Y., Li, D., Guo, J., Wang, Y., Lin, Y., & Wei, Z. (2020). IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era. Medicine, 99(21), e19883. https://doi.org/10.1097/MD.0000000000019883

Chicago

Chen, Xiangli, Yuzhu Zang, Dujuan Li, Jianmin Guo, Yacai Wang, Yuqi Lin, and Zhenghong Wei. 2020. “IDO, TDO, and AHR Overexpression Is Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era.” Medicine 99 (21): e19883. doi:10.1097/MD.0000000000019883.